Thought Leadership

Latest Report


Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Mega-deals mask a significant decline in M&A activity for pharma and medtech The Vantage Half-Year Review 2019 summaries the most significant trends across pharma, medtech and biotech in the first half of 2019. Bristol-Myers Squibb’s $74bn pending purchase of Celgene and Abbvie’s $63bn acquisition of Allergan have taken the headlines,…

Report library


EvaluatePharma Orphan Drug Report 2019

$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…


Vantage 2019 Preview

2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…